| __timestamp | ACADIA Pharmaceuticals Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 2983000000 |
| Thursday, January 1, 2015 | 90804000 | 3426000000 |
| Friday, January 1, 2016 | 186456000 | 3398000000 |
| Sunday, January 1, 2017 | 255062000 | 3878000000 |
| Monday, January 1, 2018 | 265758000 | 4056000000 |
| Tuesday, January 1, 2019 | 325638000 | 4381000000 |
| Wednesday, January 1, 2020 | 388661000 | 5151000000 |
| Friday, January 1, 2021 | 396028000 | 5246000000 |
| Saturday, January 1, 2022 | 369090000 | 5673000000 |
| Sunday, January 1, 2023 | 402466000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
In pursuit of knowledge
In the competitive world of biopharmaceuticals, operational efficiency is key. Over the past decade, Gilead Sciences, Inc. and ACADIA Pharmaceuticals Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, peaking at approximately $6.1 billion in 2023. This reflects a strategic expansion and increased operational activities. In contrast, ACADIA's expenses grew by nearly 1,130%, reaching around $402 million in the same period. This dramatic rise highlights ACADIA's aggressive growth strategy and market penetration efforts. While Gilead's expenses are significantly higher, ACADIA's rapid increase underscores its evolving market presence. These trends offer a fascinating glimpse into the financial strategies of two industry leaders, each navigating the complex landscape of biopharma with distinct approaches.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Pharming Group N.V. vs ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
Perrigo Company plc or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.